The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study-Reference-Cited by-同舟云学术

The Impact of Recombinant Human Erythropoietin Administration in Critically ill COVID-19 Patients: A Multicenter Cohort Study

Published:2023-01 Issue: Volume:29 Page:
ISSN:1076-0296
Container-title:Clinical and Applied Thrombosis/Hemostasis
language:en
Short-container-title:Clin Appl Thromb Hemost

Author:

Al Sulaiman Khalid¹²³⁴^ORCID,Aljuhani Ohoud⁵,Korayem Ghazwa B.⁶,Altebainawi Ali F.⁷⁸,Vishwakarma Ramesh⁹,AlFaifi Mashael¹⁰,Alsohimi Samiah¹¹¹²,Alrayes Aljoharah⁶,Albishi Sara⁶,Alqahtani Reem⁶,Alalawi Mai¹³¹⁴^ORCID,Al Sulaihim Ibrahim¹⁵,Alanazi Thamer A.¹⁶,Alqahtani Rahaf A.¹,Almagthali Alaa¹²,Jomah Shahamah¹⁷,Alshlowi Areej¹⁸,Alshammari Tahani R.⁷,Alzahrani Shahad S.²,Abdulqader Marwa I.²

Affiliation:

1. Pharmaceutical Care Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia

2. College of Pharmacy, King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia

3. King Abdullah International Medical Research Center, Riyadh, Saudi Arabia

4. Saudi Critical Care Pharmacy Research (SCAPE) Platform, Riyadh, Saudi Arabia

5. Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah, Saudi Arabia

6. Department of Pharmacy Practice, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia

7. Pharmaceutical Care Services, King Salman Specialist Hospital, Hail Health Cluster, Ministry of Health, Hail, Saudi Arabia

8. Department of Clinical Pharmacy, College of Pharmacy, University of Hail, Hail, Saudi Arabia

9. Norwich Medical School, University of East Anglia, Norwich, UK

10. Pharmaceutical Care Department, King Saud Medical City, Riyadh, Saudi Arabia

11. Pharmaceutical Care Services, King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia

12. Pharmaceutical Care Services, King Abdulaziz University Hospital, Jeddah, Saudi Arabia

13. Department of Pharmaceutical Sciences, Fakeeh College for Medical Sciences, Jeddah, Saudi Arabia

14. Pharmaceutical Care Department, King Abdulaziz Medical City, Jeddah, Saudi Arabia

15. Pharmaceutical Care Department, Presidency of State Security, Central Security Hospital, Riyadh, Saudi Arabia

16. Respiratory Therapy Department, King Abdulaziz Medical City, Riyadh, Saudi Arabia

17. Pharmaceutical Care Department, Dr Sulaiman Al-Habib Medical Group, Riyadh, Saudi Arabia

18. Department of Pharmacy Practice, College of Pharmacy, Almaarefa University, Riyadh, Saudi Arabia

Abstract

The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on the clinical outcomes of critically ill COVID-19 patients. A multicenter, retrospective cohort study was conducted from 01-03-2020 to 31-07-2021. We included adult patients who were ≥ 18 years old with a confirmed diagnosis of COVID-19 infection and admitted to intensive care units (ICUs). Patients were categorized depending on ESAs administration during their ICU stay. The primary endpoint was the length of stay; other endpoints were considered secondary. After propensity score matching (1:3), the overall included patients were 120. Among those, 30 patients received ESAs. A longer duration of ICU and hospital stay was observed in the ESA group (beta coefficient: 0.64; 95% CI: 0.31-0.97; P = < .01, beta coefficient: 0.41; 95% CI: 0.12-0.69; P = < .01, respectively). In addition, the ESA group's ventilator-free days (VFDs) were significantly shorter than the control group. Moreover, patients who received ESAs have higher odds of liver injury and infections during ICU stay than the control group. The use of ESAs in COVID-19 critically ill patients was associated with longer hospital and ICU stays, with no survival benefits but linked with lower VFDs.

Publisher

SAGE Publications

Subject

Hematology,General Medicine

Link

http://journals.sagepub.com/doi/pdf/10.1177/10760296231218216

Reference35 articles.

1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data. World Health Organization. https://covid19.who.int/%0Ahttps://covid19.who.int/%0Ahttps://covid19.who.int/region/searo/country/bd. Published 2021. Accessed January 19, 2023.

2. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19) — China, 2020

3. Management of critically ill patients with COVID-19 in ICU: statement from front-line intensive care experts in Wuhan, China

4. Erythropoietin as candidate for supportive treatment of severe COVID-19